Wellbutrin

(Bupropion Hydrochloride)

Phase 3Small molecule

Bupropion is used to treat depression by helping to improve mood and energy levels. It is also used to help people quit smoking by reducing cravings and withdrawal symptoms.[1] Wellbutrin is currently being investigated across 6 indications[3], with its most advanced program in Phase 3.[1]

Wellbutrin is one of 131 small molecule programs targeting Mood Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

130

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mood DisorderUnknown

Depressive DisorderUnknown

End-Stage Renal DiseaseNot yet recruiting

ObesityNot yet recruiting

Smoking CessationRecruiting

Mood DisorderPreclinical

Unknown

Depressive DisorderPreclinical

Unknown

End-Stage Renal DiseasePreclinical

Not yet recruiting

ObesityPhase 2

Not yet recruiting

Smoking CessationPhase 3

Recruiting

Competition

Competitive Landscape

190 competitors in Obesity

#DrugCompanyPhaseTrials

Maridebart Cafraglutide

Amgen

Phase 3

7 2

Wellbutrin

GSK

Phase 3

1 3

Enavogliflozin

Daewoong Pharmaceutical Co. LTD.

Phase 3

1 4

Gemtesa

Sumitomo Pharma America, Inc.

Phase 3

1 5

Berobenatide

Pfizer

Phase 3

3 6

Ribupatide

KKailera

Phase 3

3 7

Elecoglipron

AstraZeneca

Phase 3

1 8

Efsubaglutide Alfa

SShanghai Yinnuo Pharmaceutical Technology Co., Ltd.

Phase 3

1 9

Avapro

Sanofi

Preclinical

1 10

Amidate

Pfizer

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalNot yet recruiting

End-Stage Renal Disease

NCT06609343

Q4 2028

Post-ApprovalRecruiting

Smoking Cessation

NCT04604509

Q2 2031

PreclinicalNot yet recruiting

Obesity

NCT07398404

Clinical

Trials by Indication[1]

Smoking Cessation5 trials

High Dose Bupropion for Smoking Cessation - Pilot Study

Terminated·UUniversity of Southern California·Phase 2·NCT03326128·12 enrolled

Bupropion and Counseling With or Without Contingency Management to Enhance Smoking Cessation in Treating Cancer Survivors Who Continue to Smoke

Completed·NNational Institutes of Health Clinical Center (CC)·N/A·NCT00079469

Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

Terminated·WWake Forest University Health Sciences·Phase 1·NCT02582008·9 enrolled

Show 2 more trials

Effect of Smoking Cessation on Clinical and Microbiological Outcomes of the Non-surgical Periodontal Therapy

Completed·CClaudio Mendes Pannuti·N/A·NCT02744417·63 enrolled

Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial

Recruiting·MM.D. Anderson Cancer Center·Phase 4·NCT04604509·2,010 enrolled

Sexual Function3 trials

Sexual Functioning Study With Antidepressants

Completed· GSK logo

GSK·Phase 4·NCT00316160·347 enrolled

Effects Of Antidepressants On Sexual Functioning In Adults

Completed· GSK logo

GSK·Phase 3·NCT00051272·425 enrolled

Effects of Antidepressants on Sexual Functioning

Completed· GSK logo

GSK·Phase 3·NCT00051259·420 enrolled

Smoking2 trials

Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking

Completed·—·Phase 4·NCT00666978·540 enrolled

Bupropion in Helping Adults Stop Smoking

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00534001·95 enrolled

Psychiatric Disorder2 trials

Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

Completed· Pfizer logo

Pfizer·Phase 4·NCT01456936·8,144 enrolled

Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

Completed· Pfizer logo

Pfizer·Phase 4·NCT01574703·4,595 enrolled

Major Depressive Disorder1 trial

Study Of 323U66 SR In Major Depressive Disorder

Completed· GSK logo

GSK·Phase 2·NCT00135512·234 enrolled

12 more indications

Metabolism1 trial

Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT04526210·54 enrolled

Recurrence1 trial

Comparison of Nicotine Inhaler and/or Bupropion in Helping People to Stop Smoking and Prevent the Recurrence of Smoking

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00033592·1,708 enrolled

Non-Small Cell Lung Cancer1 trial

S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone Surgery

Terminated·SSWOG Cancer Research Network·Phase 3·NCT00032084·10 enrolled

Sexual Dysfunction1 trial

Bupropion in Sexual Dysfunction Among Methadone Maintenance Treatment Men

Completed·UUniversity of Malaya·Phase 2·NCT02593396·80 enrolled

Prevention1 trial

Prevention of Seasonal Affective Disorder

Completed· GSK logo

GSK·Phase 3·NCT00046241·300 enrolled

Lung Cancer1 trial

Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use

Completed·TThomas Jefferson University·N/A·NCT04694846·19 enrolled

Attention Deficit Hyperactivity Disorder (ADHD)1 trial

Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults

Completed· GSK logo

GSK·Phase 3·NCT00048360·162 enrolled

Interaction1 trial

Drug Interaction Study of Multiple Doses of Isavuconazole and a Single Dose of Bupropion

Completed· Astellas logo

Astellas·Phase 1·NCT01635972·24 enrolled

Fatigue1 trial

Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors

Active, not recruiting·UUniversity of Rochester NCORP Research Base·Phase 3·NCT03996265·422 enrolled

Depression1 trial

Seasonal Affective Depression (SAD) Study

Completed· GSK logo

GSK·Phase 1·NCT00069459·250 enrolled

End-Stage Renal Disease1 trial

Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis (BRISK)

Not yet recruiting·TThe University of Texas Health Science Center at San Antonio·Preclinical·NCT06609343·16 enrolled

Obesity1 trial

A Multiple Health Behavior Change Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients

Not yet recruiting·YYale University·Preclinical·NCT07398404·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 25 trial records for Bupropion Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bupropion Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bupropion Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Dopamine Transporter Inhibitor; Norepinephrine Transporter Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GSK

Wellbutrin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2028

Q2 2031

Trials by Indication[1]

Smoking Cessation5 trials

Sexual Function3 trials

Smoking2 trials

Psychiatric Disorder2 trials

Major Depressive Disorder1 trial

Metabolism1 trial

Recurrence1 trial

Non-Small Cell Lung Cancer1 trial

Sexual Dysfunction1 trial

Prevention1 trial

Lung Cancer1 trial

Attention Deficit Hyperactivity Disorder (ADHD)1 trial

Interaction1 trial

Fatigue1 trial

Depression1 trial

End-Stage Renal Disease1 trial

Obesity1 trial

References

Drug Info

Quick Facts

Related News